×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ALLO – allogene therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ALLO
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/16
08:30 am
allo
Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Medium
Report
Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
12/12
08:43 am
allo
Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman [Yahoo! Finance]
Medium
Report
Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman [Yahoo! Finance]
12/12
08:30 am
allo
Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman
Medium
Report
Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman
12/12
05:44 am
allo
Allogeneic T Cell Therapies Market Report, 2024-2028 & 2033 - Valued at $1.16 Billion in 2024, the Industry is Forecast to Generate Revenues of $1.69 Billion by 2028 [Yahoo! Finance]
Low
Report
Allogeneic T Cell Therapies Market Report, 2024-2028 & 2033 - Valued at $1.16 Billion in 2024, the Industry is Forecast to Generate Revenues of $1.69 Billion by 2028 [Yahoo! Finance]
12/2
02:49 pm
allo
Allogene Therapeutics Loses 23% Year to Date: How to Play the Stock? [Yahoo! Finance]
Low
Report
Allogene Therapeutics Loses 23% Year to Date: How to Play the Stock? [Yahoo! Finance]
11/19
08:30 am
allo
Allogene Therapeutics Announces Participation in December Investor Conferences
Low
Report
Allogene Therapeutics Announces Participation in December Investor Conferences
11/18
08:35 am
allo
Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence [Yahoo! Finance]
Medium
Report
Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence [Yahoo! Finance]
11/18
08:30 am
allo
Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence
High
Report
Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence
Date
Time
Symbol
Company Name
Action
%Chg
11/7/2024
04:02 pm
allo
allogene therapeutics, inc.
BEAT
Report
-3.4%
allogene therapeutics, inc.
8/7/2024
04:02 pm
allo
allogene therapeutics, inc.
IN-LINE
Report
-4.5%
allogene therapeutics, inc.
5/13/2024
04:01 pm
allo
allogene therapeutics, inc.
BEAT
Report
2.1%
allogene therapeutics, inc.
3/14/2024
04:05 pm
allo
allogene therapeutics, inc.
MISS
Report
1.3%
allogene therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/10
04:54 pm
allo
Form 4 Allogene Therapeutics, For: Dec 09 Filed by: MESSEMER DEBORAH M.
Low
Report
Form 4 Allogene Therapeutics, For: Dec 09 Filed by: MESSEMER DEBORAH M.
12/9
04:06 pm
allo
Form 4 Allogene Therapeutics, For: Dec 05 Filed by: Humer Franz B
Medium
Report
Form 4 Allogene Therapeutics, For: Dec 05 Filed by: Humer Franz B
12/9
04:03 pm
allo
Form 144 Allogene Therapeutics, Filed by: MESSEMER DEBORAH M.
Medium
Report
Form 144 Allogene Therapeutics, Filed by: MESSEMER DEBORAH M.
12/4
02:16 pm
allo
Form 144/A Allogene Therapeutics, Filed by: Humer Franz B
Low
Report
Form 144/A Allogene Therapeutics, Filed by: Humer Franz B
12/2
02:12 pm
allo
Form 144 Allogene Therapeutics, Filed by: Humer Franz B
Low
Report
Form 144 Allogene Therapeutics, Filed by: Humer Franz B
11/13
04:30 pm
allo
Form 8-K Allogene Therapeutics, For: Nov 11
Medium
Report
Form 8-K Allogene Therapeutics, For: Nov 11
11/12
01:27 pm
allo
Form SC 13G/A Allogene Therapeutics, Filed by: VANGUARD GROUP INC
Low
Report
Form SC 13G/A Allogene Therapeutics, Filed by: VANGUARD GROUP INC
11/8
02:20 pm
allo
Form SC 13G/A Allogene Therapeutics, Filed by: BlackRock, Inc.
Low
Report
Form SC 13G/A Allogene Therapeutics, Filed by: BlackRock, Inc.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
2/6
Allogene Therapeutics Announces February and March 2020 Investor Conference Schedule
6.8%
3/18 Form 4 Allogene Therapeutics, For: Mar 16 Filed by: Chang David D 6.8%
3/17 Allogene Therapeutics Inc (NASDAQ: ALLO) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 6.7%
4/23 Form DEF 14A Allogene Therapeutics, For: Dec 31 5.9%
4/28 Form 4 Allogene Therapeutics, For: Apr 24 Filed by: Chang David D 5.9%
4/17 Allogene Therapeutics Inc (NASDAQ: ALLO) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 5.5%
8/7 Allogene Therapeutics, Inc. (ALLO) CEO David Chang on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] 5.0%
3/24 MaxCyte and Allogene Therapeutics Sign Clinical and Commercial License Agreement to Enable the Advancement of Allogeneic CAR T (AlloCAR T™) Therapies 4.9%
3/13 Allogene Therapeutics Inc (NASDAQ: ALLO) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $35.00 price target on the stock. 4.7%
2/24 Form 4 Allogene Therapeutics, For: Feb 20 Filed by: SCHMIDT ERIC THOMAS 4.4%
3/18 Form 4 Allogene Therapeutics, For: Mar 16 Filed by: Chang David D 6.8%
3/17 Allogene Therapeutics Inc (NASDAQ: ALLO) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 6.7%
4/23 Form DEF 14A Allogene Therapeutics, For: Dec 31 5.9%
4/28 Form 4 Allogene Therapeutics, For: Apr 24 Filed by: Chang David D 5.9%
4/17 Allogene Therapeutics Inc (NASDAQ: ALLO) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 5.5%
8/7 Allogene Therapeutics, Inc. (ALLO) CEO David Chang on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] 5.0%
3/24 MaxCyte and Allogene Therapeutics Sign Clinical and Commercial License Agreement to Enable the Advancement of Allogeneic CAR T (AlloCAR T™) Therapies 4.9%
3/13 Allogene Therapeutics Inc (NASDAQ: ALLO) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $35.00 price target on the stock. 4.7%
2/24 Form 4 Allogene Therapeutics, For: Feb 20 Filed by: SCHMIDT ERIC THOMAS 4.4%
TOP News Decliners
3/12
Allogene Therapeutics Inc (NASDAQ: ALLO) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating.
-15.8%
11/6 Allogene Therapeutics Inc (NASDAQ: ALLO) had its "hold" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $29.00 price target on the stock. -6.4%
8/11 Allogene Therapeutics Inc (NASDAQ: ALLO) had its "hold" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $29.00 price target on the stock. -5.4%
8/12 Allogene Therapeutics Inc (NASDAQ: ALLO) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.2%
3/20 Senator Richard Burr Sold a Fortune in Stocks While Playing Down Coronavirus Threat [The New York Times] -5.1%
11/12 Allogene Moves Forward With CAR-T Therapy Pipeline [Seeking Alpha] -5.1%
4/1 Allogene Therapeutics Announces Participation in Two Upcoming Virtual Investor Conferences -4.9%
9/25 Form 4 Allogene Therapeutics, For: Sep 23 Filed by: Kazam Joshua A -4.8%
5/22 Allogene Therapeutics Inc (NASDAQ: ALLO) is now covered by analysts at Stifel Nicolaus. They set a "hold" rating on the stock. -4.8%
11/5 Q3/2019 9/30/2019 EPS -0.500 ZacksConsensus -0.540 ActVsEst 0.040 - Beat -4.4%
11/6 Allogene Therapeutics Inc (NASDAQ: ALLO) had its "hold" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $29.00 price target on the stock. -6.4%
8/11 Allogene Therapeutics Inc (NASDAQ: ALLO) had its "hold" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $29.00 price target on the stock. -5.4%
8/12 Allogene Therapeutics Inc (NASDAQ: ALLO) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.2%
3/20 Senator Richard Burr Sold a Fortune in Stocks While Playing Down Coronavirus Threat [The New York Times] -5.1%
11/12 Allogene Moves Forward With CAR-T Therapy Pipeline [Seeking Alpha] -5.1%
4/1 Allogene Therapeutics Announces Participation in Two Upcoming Virtual Investor Conferences -4.9%
9/25 Form 4 Allogene Therapeutics, For: Sep 23 Filed by: Kazam Joshua A -4.8%
5/22 Allogene Therapeutics Inc (NASDAQ: ALLO) is now covered by analysts at Stifel Nicolaus. They set a "hold" rating on the stock. -4.8%
11/5 Q3/2019 9/30/2019 EPS -0.500 ZacksConsensus -0.540 ActVsEst 0.040 - Beat -4.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: